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ABSTRACT
Purpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for 
hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in 
postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole 
according to estrogen receptor (ER) expression levels.
Methods: In this multi-institutional, open-label, observational study, postmenopausal 
patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years 
unless they experienced disease progression or unacceptable toxicity or withdrew their 
consent. The patients were stratified into the following 3 groups according to ER expression 
levels using a modified Allred score (AS): low, intermediate, and high (AS 3–4, 5–6, and 7–8, 
respectively). ER expression was centrally reviewed. The primary objective was the 5-year 
disease-free survival (DFS) rate.
Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With 
a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% 
confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) 
rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 
94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the 
corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 
25 patients discontinued letrozole because of drug toxicity.
Conclusion: Treatment with adjuvant letrozole showed very favorable treatment outcomes 
and good tolerability among Korean postmenopausal women with ER-positive breast cancer, 
independent of ER expression.
Trial Registration: ClinicalTrials.gov Identifier: NCT01069211
Keywords: Breast neoplasms; Letrozole; Postmenopause; Receptors, estrogen
INTRODUCTION
Approximately 75% of breast cancers express the estrogen receptor (ER) [1], and anti-
estrogen treatment is the standard-of-care for patients with these tumors [2]. For 
postmenopausal patients with ER-positive breast cancer, either tamoxifen or aromatase 
inhibitors are prescribed for 5 to 10 years, taking into account drug tolerability and patient 
risk factors, such as tumor stage and genomic profile [3,4]. Aromatase inhibitors, such 
as letrozole and anastrozole, have been used in clinical practice and are preferred over 
tamoxifen for postmenopausal women with ER-positive tumors because they induce superior 
survival outcomes [5-7].
Factors predicting patient responses to endocrine therapy have been investigated to evaluate 
the risk of endocrine therapy failure and tailor anti-estrogen therapy [8-10]. Several lines of 
evidence suggest that the ER expression level is associated with the response to endocrine 
therapy [11,12]. In addition, a high ESR1 messenger RNA level has been shown to be 
associated with the benefit of tamoxifen [13]. Thus, using a prospective study, it is important 
to investigate whether survival outcomes vary according to ER expression levels.
In this present study, we aimed to compare clinical outcomes according to ER expression 
level in postmenopausal women with ER-positive breast cancer who were treated with 
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letrozole as an adjuvant endocrine therapy. We analyzed the survival outcomes and toxicity of 
letrozole in the intention-to-treat (ITT) population.
METHODS
Study design and participants
This was a multi-institutional, open-label, observational trial that evaluated the clinical 
outcomes of Korean postmenopausal women with ER-positive breast cancer receiving 
adjuvant letrozole after surgical intervention. Women from 44 institutes participated in 
this study. Women who were ≥ 55 years old or < 55 years old but had postmenopausal levels 
of follicle-stimulating hormone (i.e., ≥ 30 mIU/mL) and were amenorrheic for at least 12 
consecutive months before letrozole treatment or had undergone a bilateral oophorectomy 
were considered eligible for this trial. Eligible patients underwent either breast-conserving 
therapy or mastectomy with axillary staging. All patients had operable, ER-positive, 
invasive breast cancer, which was confirmed using histology. Systemic chemotherapy was 
administered to patients who were at risk of recurrence based on the treatment principles of 
the individual institutes. The tumor, nodes, and metastases (TNM) staging was performed 
according to the 7th edition of the American Joint Committee on Cancer system [14]. ER 
expression was reviewed centrally using the following modified Allred score (AS): low (AS 
3–4), intermediate (AS 5–6), and high (AS 7–8) [15].
Procedures
Enrolled patients received letrozole (2.5 mg) as an oral tablet once daily until they 
experienced disease progression or unacceptable toxicity, or withdrew consent, and the 
treatment ended 5 years from the date of the first dose, regardless of any missed doses. 
Patients were required to have an annual physical examination during the study period. 
Moreover, they were followed up with physical examinations every 6 months during the 
study period and every 12 months thereafter. A bilateral mammogram was required every 
12 months, and bone mineral density tests were required every 1 or 2 years during the study 
period. Additional radiological studies were allowed based on the protocols of each institute. 
Serum lipid tests were conducted every 6 months during therapy. Adverse events (AEs) were 
assessed based on the Common Terminology Criteria for Adverse Events (version 3.0) every 6 
months during treatment. All procedures were performed in accordance with the guidelines 
for Good Clinical Practice and the Declaration of Helsinki, and the study was approved by 
the institutional ethics committees of each hospital and the Institutional Review Board (IRB) 
of the Korean Breast Cancer Society. Written informed consent was obtained from each 
participant. The local IRB number of **** hospital is 3-2010-0042, and this trial is registered 
with ClinicalTrials.gov (number NCT01069211).
Outcomes
The primary endpoint was disease-free survival (DFS), which was defined as the time from 
the operation to breast cancer recurrence, second primary malignancy, or death. Secondary 
endpoints were drug toxicity, overall survival (OS), invasive cancer recurrence-free survival 
(RFS; time from the operation to local, regional, or distant metastasis of breast cancer or 
contralateral breast cancer as a first event), and distant metastasis-free survival (DMFS; time 
from the operation to distant metastasis of breast cancer).
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Statistical analysis
The primary end-point, DFS, was evaluated according to ER expression status. We 
hypothesized that the DFS of the high expression group (AS 7–8) would be longer than that of 
the intermediate (AS 5–6) and low (AS 3–4) expression groups. Based on historical data, the 
DFS rates were expected to be 70.4%, 84.0%, and 93.6 for the low, intermediate, and high 
expression groups, respectively [15,16]. A sample size of 174 for each group would achieve 
80% power to detect a DFS superiority of 9.6% between the high and intermediate groups 
with a two-sided type I error rate of 1.67% and a drop rate of 20%. In December 2013, the 
protocol was amended to compare survival outcomes between the high expression (AS 7–8) 
and a combined low-to-intermediate (AS 3–6) group because the number of patients in the 
low expression (AS 3–4) group was much lower than anticipated. Recruitment was closed in 
February 2014, and 440 patients were included.
The Kaplan-Meier method was used to estimate DFS, RFS, DMFS, and OS, and the estimated 
survival curves were compared using the log-rank test. Cox proportional hazard-regression 
model was used to calculate hazard ratios and 95% confidence intervals (CIs). All statistical 
analyses were performed using R (http://www.r-project.org) software and a p-value < 0.05 
was considered statistically significant.
Role of the funding sources
The funders provided the study drug (letrozole) and collaborated with the authors on 
the study design and data collection methods. All authors contributed to drafting the 
manuscript, provided final approval to publish, and agreed to be accountable for all aspects 
of the manuscript.
RESULTS
Between April 25, 2010, and February 5, 2014, 440 patients were enrolled and their data were 
available for the ITT analysis. Of the 440 patients, 314 (71.3%) completed the study, whereas 
126 (28.7%) discontinued letrozole. The main reasons for discontinuation of the study drug 
were loss to follow-up (28.6%), AEs (20.6%), and tumor recurrence (17.5%). Other reasons 
for discontinuation are presented in Table 1.
The demographic characteristics of the study patients are listed in Table 2. The median 
age of the enrolled patients was 57 (range, 43–81) years. Approximately 70% of the patients 
had a T1 tumor or node-negative disease. Furthermore, 247 and 159 of the 440 (56.1% and 
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Table 1. Reasons for discontinuation of study drug in intention-to-treat population
Category Values
Enrolled subjects 440 (100.0)
Completed study 314 (71.3)
Discontinued letrozole 126 (28.7)
Reasons for letrozole discontinuation
Follow-up loss 36 (28.6)
Adverse event 25 (19.8)
Tumor recurrence 22 (17.5)
Consent withdrawal 17 (13.5)
Protocol violation 16 (12.7)
Unknown 10 (7.9)
Values are presented as number (%).
36.1%) patients had stage I and stage II disease, respectively, whereas 33 (7.5%) had stage III 
disease. The percentages of patients categorized as exhibiting low, intermediate, or high ER 
expression by AS were 11.1%, 23.7%, and 65.2%, respectively. Most (304, 69.1%) patients 
were progesterone receptor (PR) positive, whereas 77 (17.5%) patients had human epidermal 
growth factor receptor-2 (HER2)-positive breast cancer. Approximately 60% of patients 
underwent breast-conserving surgery and 54.8% received chemotherapy.
When we compared the clinical characteristics according to ER expression, the low-to-
intermediate ER group showed a higher rate of PR-negative, HER2-positive, and high 
histologic grade than the high ER group, whereas the anatomical stage was not different 
between both groups (Table 3). More patients in the ER low-to-intermediate group received 
adjuvant chemotherapy (62.1% vs. 50.9%; p = 0.031) than those in the ER high group. The 
median follow-up was 62.0 months and there were 3 mortalities, whereas 22, 17, 1, and 5 
patients experienced breast cancer recurrences, metastases, contralateral breast cancer, 
and other primary malignancies, respectively. One and two patients died because of acute 
subarachnoid hemorrhage and breast cancer progression, respectively.
168https://ejbc.kr https://doi.org/10.4048/jbc.2021.24.e17
Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women
Table 2. Baseline characteristics of study participants (n = 440)
Characteristics Values






























I, II 271 (61.6)
III 89 (20.2)
Unknown 80 (18.2)
Values are presented as median (range) or number (%).
ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
Furthermore, the 5-year DFS rate of all the patients was 94.2% (95% CI, 91.8–96.6). The 
5-year DFS and RFS rates did not differ according to ER expression (5-year DFS, 94.3% 
and 94.1% in the low-to-intermediate and high groups, respectively, p = 0.6; 5-year RFS, 
95.7% and 95.4% in the low-to-intermediate and high groups, p = 0.7; Figure 1A and B). The 
DMFS and OS rates also did not differ according to ER expression (Figure 1C and D), and 
clinical outcomes did not differ among the three groups categorized based on ER expression 
(Supplementary Figure 1). However, all survival outcomes differed significantly based on 
TNM staging (Figure 2).
Chemotherapy was administered more frequently in the low-to-intermediate group than in 
the high group; therefore, we performed multivariable survival analyses using chemotherapy 
administration, ER expression, and stage as factors. Multivariable analyses showed that stage 
was the only significant prognostic factor for DFS and RFS (Supplementary Table 1).
The AEs associated with letrozole were investigated and 25 patients discontinued the drug 
because of toxicity (Figure 3). The AE most commonly associated with drug discontinuation 
was arthralgia (18, 4%). Other AEs leading to drug discontinuation were hot flushes (n = 1),  
skin rash (n = 1), headache (n = 1), dyspnea (n = 1), liver function abnormality (n = 1), 
gastrointestinal disorder (n = 1), subarachnoid hemorrhage, and unknown (n = 1).
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Table 3. Baseline characteristics of study participants (n = 440) by estrogen receptor expression level
Characteristics High (n = 287) Low-to-intermediate (n = 153) p-value
Age (yr) 58.7 ± 8.4 59.3 ± 7.8 0.501
T stage* 0.724
1 201 (70.3) 103 (67.3)
2 78 (27.3) 47 (30.7)
3 7 (2.4) 3 (2.0)
N stage* 0.106
0 215 (75.4) 107 (70.4)
1 47 (16.5) 37 (24.3)
2 11 (3.9) 6 (3.9)
3 12 (4.2) 2 (1.3)
Stage* 0.236
1 166 (58.0) 81 (52.9)
2 96 (33.6) 63 (41.2)
3 24 (8.4) 9 (5.9)
PR status* < 0.001
Positive 216 (75.8) 88 (57.9)
Negative 69 (24.2) 64 (42.1)
HER2 status* < 0.001
Negative 246 (88.5) 100 (69.0)
Positive 32 (11.5) 45 (31.0)
Histologic grade* 0.003
I, II 186 (80.5) 85 (65.9)
III 45 (19.5) 44 (34.1)
Chemotherapy 0.031
Yes 146 (50.9) 95 (62.1)
No 141 (49.1) 58 (37.9)
Data are shown as mean ± standard deviation or number (%).
PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
*Missing values are included.
DISCUSSION
Our study did not demonstrate different clinical outcomes in the investigated study 
population based on ER expression levels. Several factors might have contributed to this 
negative finding. First, we assumed that the clinical benefit of endocrine therapy might be 
biologically correlated with the ER expression level, and a few studies in the adjuvant setting 
have demonstrated this relationship using either the ER H-score [17] or ESR1 expression 
level [13]. These studies uniformly included cohorts treated with tamoxifen or no systemic 
therapy. However, modern systemic chemotherapy is guided by clinical and biological 
risk stratification. Therefore, in this trial, more than half of the patients (54.8%) received 
adjuvant chemotherapy, which did not affect survival among groups with different ER 
expression levels.
Our study population showed very favorable outcomes with a 5-year DFS of 96.0%. This 
excellent outcome made it difficult to discriminate survival outcomes according to ER 
expression. Because a linear relationship between the response to neoadjuvant letrozole and 
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287 (0) 251 (35) 231 (51) 177 (113) 0 (268)
153 (0) 139 (10) 133 (15) 112 (50) 1 (144)
No. at risk (No. censored)
ER expression
Figure 1. Clinical outcomes according to ER expression level (high, AS 7–8; low-to-intermediate, AS 3–6). Survival curves were generated using the Kaplan-Meier 
method. All p values were calculated using the log-rank test. (A) DFS (p = 0.6), (B) RFS (p = 0.7), (C) DMFS (p = 0.5), and (D) OS (p = 0.3). 
ER = estrogen receptor; AS = Allred score; DFS = disease-free survival; RFS = recurrence-free survival; DMFS = distant metastasis-free survival; OS = overall survival.
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Figure 3. AEs leading to drug discontinuation. 
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Figure 2. Clinical outcome according to tumor, nodes, and metastases stage. Survival curves were generated using the Kaplan-Meier method. All p-values were 
calculated using the log-rank test. (A) DFS (p = 0.04), (B) RFS (p = 0.001), (C) DMFS (p = 0.001), and (D) OS (p < 0.001). 
DFS = disease-free survival; RFS = recurrence-free survival; DMFS = distant metastasis-free survival; OS = overall survival.
ER expression was observed in the letrozole 024 trial [18], a much larger number of patients 
would be needed to demonstrate a survival difference according to ER expression status.
The very good outcomes observed in our study were comparable to those observed in two other large 
trials of adjuvant aromatase inhibitors; where the 5-year DFS was 87.9% in the Breast International 
Group (BIG) 1-98 study [19] and the 4-year DFS was 86.9% in the Arimidex, Tamoxifen Alone or in 
Combination (ATAC) study [20]. Approximately 30% of our patients had node-positive and T2-3 
tumors, whereas approximately 40% of the study population in the BIG 1-98 and ATAC studies had 
nodal involvement [16,21]. This observation indicates that our results might not be exceptional.
In addition, our study population showed good drug compliance and 71.3% of patients 
completed 5 years of letrozole treatment (Table 1). This completion rate is very similar to that 
observed in the BIG 1-98 study (71.1%) [22]. Because the survival of patients with good drug 
adherence is superior to that of patients with poor drug adherence [22-24], encouraging drug 
compliance is an effective strategy for improving outcomes.
Arthralgia is a well-known AE associated with aromatase inhibitors [25,26] and the most 
common cause of treatment discontinuation. Eighteen patients stopped taking the study 
drug because of arthralgia. Recent clinical trials and meta-analyses suggest that acupuncture 
could reduce aromatase inhibitor-induced arthralgia [27,28]. In addition, previous trials also 
showed that exercise can mitigate the joint pain induced by aromatase inhibitors [29,30]. 
Therefore, endorsement of interventional strategies such as acupuncture and exercise could 
relieve drug-induced arthralgia and increase drug compliance.
Our study has one major limitation of having enrolled fewer patients than expected. In 
addition, the low number of disease events made it difficult to estimate the predictive value of 
ER expression level and identify other prognostic factors. Moreover, adjuvant chemotherapy 
was administered more frequently in the low-to-intermediate group than it was in the high 
group, which could potentially affect survival outcomes. Despite these limitations, our study 
supports the current efficacy and safety of the use of letrozole and provides reassuring evidence 
that might increase drug compliance in patients. Because ER-positive breast cancer has the risk 
of late recurrence after 5 years, further studies with a longer follow-up are warranted.
In conclusion, our study findings revealed that treatment with adjuvant letrozole provided a 
very favorable treatment outcome and showed good tolerability in Korean postmenopausal 
women with ER-positive breast cancer, independent of ER expression status.
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Supplementary Figure 1
Clinical outcomes in three groups divided according to ER expression levels (high, AS 7–8; 
intermediate, AS 5–6; low, AS 3–4). Survival curves were generated using the Kaplan-Meier 
method. All p-values were calculated using the log-rank test. (A) DFS (p = 0.4), (B) RFS (p = 
0.5), (C) DMFS (p = 0.4), and (D) OS (p = 0.4).
Click here to view
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